Variant report
Variant | esv3368362 |
---|---|
Chromosome Location | chr5:29544095-29548293 |
allele | n/a |
Outlinks | Ensembl   UCSC |
- TF binding region (count:0)
- CpG islands (count:0)
- Chromatin interactive region (count:0)
- LncRNA region (count:0)
- Mature miRNA region (count: 0)
- miRNA target sites (count:0)
No data |
No data |
No data |
No data |
No data |
No data |
No data |
No. | Variant name | Chromosome position | Chromatin state | Related regulatory elements | Target genes | Extended variants | Associated traits |
---|---|---|---|---|---|---|---|
1 | rs78610158 | chr5:29544098-29544099 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
2 | rs371124958 | chr5:29544130-29544131 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
3 | rs532755620 | chr5:29544140-29544141 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
4 | rs551364186 | chr5:29544288-29544289 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
5 | rs117426006 | chr5:29544294-29544295 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
6 | rs535378527 | chr5:29544314-29544315 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
7 | rs72751448 | chr5:29544319-29544320 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
8 | rs573761566 | chr5:29544330-29544331 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
9 | rs556633419 | chr5:29544332-29544333 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
10 | rs111353759 | chr5:29544364-29544365 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
11 | rs649343 | chr5:29544412-29544413 | Enhancers Weak transcription | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
12 | rs191343438 | chr5:29544438-29544439 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
13 | rs183524734 | chr5:29544463-29544464 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
14 | rs141173256 | chr5:29544479-29544480 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
15 | rs79780354 | chr5:29544515-29544516 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
16 | rs187762412 | chr5:29544516-29544517 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
17 | rs547005470 | chr5:29544569-29544570 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
18 | rs687233 | chr5:29544575-29544576 | Enhancers Weak transcription | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
19 | rs561843450 | chr5:29544576-29544577 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
20 | rs367608323 | chr5:29544602-29544603 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
21 | rs192254886 | chr5:29544687-29544688 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
22 | rs544432134 | chr5:29544700-29544701 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
23 | rs687686 | chr5:29544701-29544702 | Weak transcription Enhancers | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
24 | rs647922 | chr5:29544747-29544748 | Weak transcription Enhancers | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
25 | rs115139216 | chr5:29544918-29544919 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
26 | rs560136757 | chr5:29544940-29544941 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
27 | rs10670544 | chr5:29544944-29544945 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
28 | rs33931491 | chr5:29544945-29544946 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
29 | rs386403414 | chr5:29544946-29544947 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
30 | rs3029089 | chr5:29544947-29544948 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
31 | rs528767911 | chr5:29545068-29545069 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
32 | rs62354953 | chr5:29545072-29545073 | Weak transcription Enhancers | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
33 | rs568436409 | chr5:29545152-29545153 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
34 | rs529412919 | chr5:29545158-29545159 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
35 | rs184524 | chr5:29545166-29545167 | Weak transcription Enhancers | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | mRNA abundance |
36 | rs569208661 | chr5:29545171-29545172 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
37 | rs539962183 | chr5:29545236-29545237 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
38 | rs582383 | chr5:29545250-29545251 | Weak transcription Enhancers | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
39 | rs76538843 | chr5:29545277-29545278 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
40 | rs150300314 | chr5:29545306-29545307 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
41 | rs368673992 | chr5:29545325-29545326 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
42 | rs116268083 | chr5:29545330-29545331 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
43 | rs550776227 | chr5:29545361-29545362 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
44 | rs570523631 | chr5:29545370-29545371 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
45 | rs539565858 | chr5:29545441-29545442 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
46 | rs544373383 | chr5:29545444-29545445 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
47 | rs556442548 | chr5:29545495-29545496 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
48 | rs577656872 | chr5:29545538-29545539 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
49 | rs545125452 | chr5:29545549-29545550 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
50 | rs184993486 | chr5:29545551-29545552 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
Disease | PMID | Source |
---|---|---|
Medulloblastoma | 21979893 | CNVD |
Myofibroblastic sarcoma | 19369631 | CNVD |
Cervical squamous cell carcinoma | 21590768 | CNVD |
Non-small cell lung cancer | 20864512 | CNVD |
Esophageal squamous carcinoma | 21637470 | CNVD |
Glioblastoma multiforme | 21080181 | CNVD |
Medulloblastoma | 16783165 | CNVD |
Thyroid cancer | 19087340 | CNVD |
Liposarcoma | 21253554 | CNVD |
Pancreatic endocrine tumor | 17639061 | CNVD |
Cervical Cancer | 21857958 | CNVD |
Cervical cancer | 21062161 | CNVD |
Ewing''s sarcoma | 21437220 | CNVD |
Glioblastoma multiforme | 19960244 | CNVD |
Oral cancer | 21386901 | CNVD |
Astrocytoma | 17387387 | CNVD |
Breast cancer | 21264507 | CNVD |
Acute lymphoblastic leukemia | 20067559 | CNVD |
Esophageal squamous carcinoma | 18350619 | CNVD |
Ewing''s sarcoma | 17952124 | CNVD |
Malignant mesothelioma | 18160781 | CNVD |
Pleural malignant mesothelioma | 18160781 | CNVD |
Cervical cancer | 18559093 | CNVD |
Basal cell lymphoma | 16317097 | CNVD |
Diffuse large b-cell lymphoma | 16317097 | CNVD |
Metanephric adenoma | 20802469 | CNVD |
Acute lymphoblastic leukemia | 17690704 | CNVD |
Gastrointestinal stromal cancer | 16982739 | CNVD |
Phyllodes tumor | 17334353 | CNVD |
Malaria | 21533027 | CNVD |
Renal cell carcinoma | 19461508 | CNVD |
Colorectal cancer | 21645411 | CNVD |
Gastric cancer | 22152101 | CNVD |
Oesophago-gastric ulcer | 22152101 | CNVD |
Ovarian cancer | 21781307 | CNVD |
Breast cancer | 20668451 | CNVD |
Cancer | 20668451 | CNVD |
Lung cancer | 20668451 | CNVD |
Ovarian cancer | 20668451 | CNVD |
Pancreas cancer | 20668451 | CNVD |
Prostate cancer | 20668451 | CNVD |
Cancer | 20164919 | CNVD |
Acute lymphoblastic leukemia | 20435627 | CNVD |
T-cell prolymphocytic leukemia | 19278963 | CNVD |
Thoracic aortic aneurysm | 21092924 | CNVD |
Multiple myeloma | 17550852 | CNVD |
prenatal diagnosis | 22389664 | CNVD |
Bladder cancer | 21909424 | CNVD |
DNA damage stimulus | 22844521 | CNVD |
DNA repair | 22844521 | CNVD |
Breast cancer | 21785460 | CNVD |
Spinal muscular atrophy | 22422766 | CNVD |
Spinal muscular atrophy | 22558076 | CNVD |
Spinal muscular atrophy | 21320981 | CNVD |
Spinal muscular atrophy | 21762474 | CNVD |
Breast cancer | 21858162 | CNVD |
Esophageal adenocarcinoma | 19417022 | CNVD |
Cancer | 16751803 | CNVD |
Breast cancer | 16608533 | CNVD |
Autism | 22495311 | CNVD |
Melanoma | 18172304 | CNVD |
Non-syndromic sensorineural hearing loss | 20606397 | CNVD |
Intellectual disability | 22102821 | CNVD |
Prostate cancer | 21965145 | CNVD |
Cancer | 21183584 | CNVD |
Ovarian cancer | 20844748 | CNVD |
Myeloproliferative neoplasm | 20015882 | CNVD |
Breast cancer | 17603634 | CNVD |
Gastrointestinal stromal cancer | 20818650 | CNVD |
Non-small cell lung cancer | 19010865 | CNVD |
Glioblastoma multiforme | 22286061 | CNVD |
Compulsive disorder | 18923513 | CNVD |
Epilepsy | 18923513 | CNVD |
Prader-willi syndrome | 18923513 | CNVD |
small cell lung cancer | 20016488 | CNVD |
Ovarian cancer | 21720365 | CNVD |
Lung cancer | 18438408 | CNVD |
Chronic lymphocytic leukemia | 21546498 | CNVD |
Glioma | 20126413 | CNVD |
Non-small cell lung cancer | 21829676 | CNVD |
Breast cancer | 22032731 | CNVD |
Esophageal cancer | 20955586 | CNVD |
Prostate cancer | 18632612 | CNVD |
Breast cancer | 21364760 | CNVD |
Breast cancer | 20409316 | CNVD |
Medulloblastoma | 19270706 | CNVD |
Breast cancer | 19553991 | CNVD |
Lung cancer | 19553991 | CNVD |
Melanoma | 19553991 | CNVD |
Ovarian cancer | 19553991 | CNVD |
Prostate cancer | 19553991 | CNVD |
Non-small cell lung cancer | 17156491 | CNVD |
Breast cancer | 17133270 | CNVD |
Non-syndromic sensorineural hearing loss | 21293372 | CNVD |
Myelofibrosis | 22110671 | CNVD |
Schizophrenia | 18923514 | CNVD |
Schizophrenia | 22241247 | CNVD |
No. | Chromosome Location | Chromatin state | Cell line | Tissue |
---|---|---|---|---|
1 | chr5:29543200-29545200 | Enhancers | Primary hematopoietic stem cells G-CSF-mobilized Female | -- |
2 | chr5:29543400-29547400 | Enhancers | Primary hematopoietic stem cells G-CSF-mobilized Male | -- |
3 | chr5:29543600-29544600 | Enhancers | H1 BMP4 Derived Trophoblast Cultured Cells | ES cell derived |
4 | chr5:29544000-29544400 | Enhancers | Primary hematopoietic stem cells | blood |
5 | chr5:29544400-29547600 | Weak transcription | Primary hematopoietic stem cells | blood |
6 | chr5:29544600-29548200 | Weak transcription | H1 BMP4 Derived Trophoblast Cultured Cells | ES cell derived |
7 | chr5:29545200-29546400 | Weak transcription | Primary hematopoietic stem cells G-CSF-mobilized Female | -- |
8 | chr5:29546400-29548800 | Enhancers | Primary hematopoietic stem cells G-CSF-mobilized Female | -- |
9 | chr5:29547400-29548000 | Flanking Active TSS | Primary hematopoietic stem cells G-CSF-mobilized Male | -- |
10 | chr5:29547600-29548400 | Enhancers | Primary hematopoietic stem cells | blood |
11 | chr5:29548000-29548600 | Enhancers | Primary hematopoietic stem cells G-CSF-mobilized Male | -- |
12 | chr5:29548200-29550000 | Enhancers | H1 BMP4 Derived Trophoblast Cultured Cells | ES cell derived |